GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM
(OTTAWA, March 22, 2023) Genomadix , based in Ottawa, Canada, announced today the US Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of its “Genomadix CubeTM CYP2C19 System” …
22/03/23
Read More
Read GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM
Genomadix Inc. Announces Know-How License Agreement with Mayo Clinic
OTTAWA, ON, Aug. 29, 2022 /CNW/ – Genomadix today announced it has entered into a know-how license agreement and stock purchase agreement with Mayo Clinic to advance its point of care molecular …
29/08/22
Read More
Read Genomadix Inc. Announces Know-How License Agreement with Mayo Clinic
GENOMADIX ANNOUNCES SECURING TWO YEARS OF FUNDING
GENOMADIX ANNOUNCES SECURING TWO YEARS OF FUNDING Diagnostic Provider Poised for Significant Growth Upon Market Authorization (OTTAWA, July 18, 2022) Genomadix , based in Ottawa, Canada, today announced that a …
20/07/22
Read More
Read GENOMADIX ANNOUNCES SECURING TWO YEARS OF FUNDING
Spartan Bioscience Now Genomadix Inc.
OTTAWA, September 17th, 2021 – Spartan Bioscience Inc. (Spartan) announces today that its primary assets have been acquired by Genomadix Inc. (Genomadix) a new company formed to carry on Spartan’s mission. …
21/09/21
Read More
Read Spartan Bioscience Now Genomadix Inc.